Track Monte Rosa Therapeutics Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Monte Rosa Therapeutics Inc. Common Stock GLUE · Stock Open Monte Rosa Therapeutics Inc. Common Stock in new tab

9.37 USD
P/E
49.25
EPS
-1.39
P/B
2.63
ROE
-35.30
Beta
1.38
Target Price
25.38 USD
Loading chart...
Key Metrics
Earnings dateMarch 16, 2027
P/E49.25
EPS-1.39
Book Value3.56
Price to Book2.63
Debt/Equity7.31
% Insiders0.746%
Growth
Revenue Growth3.26%
Estimates
Forward P/E-5.19
Forward EPS-1.81
Target Mean Price25.38

DCF valuation

Model fair value for Monte Rosa Therapeutics Inc. Common Stock (GLUE)
Result
Sign in to run the valuation for GLUE.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
8 analysts · consensus Strong buy · mean target 25.38 USD (low 15.00, high 37.00) · as of 15 Nov 2026
Low 15.00
Mean 25.38
High 37.00
Price 9.37
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Monte Rosa Therapeutics Inc. Common Stock Logo Monte Rosa Therapeutics Inc. Common Stock Analysis (GLUE)

United States Health Care Official Website Stock

Is Monte Rosa Therapeutics Inc. Common Stock a good investment? Monte Rosa Therapeutics Inc. Common Stock (GLUE) is currently trading at 9.37 USD. Market analysts have a consensus price target of 25.38 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 49.25. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: Monte Rosa Therapeutics Inc. Common Stock is expected to release its next earnings report on March 16, 2027. The market consensus estimate for Forward EPS is -1.81.

Investor FAQ

Does Monte Rosa Therapeutics Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Monte Rosa Therapeutics Inc. Common Stock?

Monte Rosa Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 16, 2027. The company currently has a trailing EPS of -1.39.

Company Profile

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Exchange Ticker
NMS (United States) GLUE
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion